Latest News and Press Releases

Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announces today that the positive efficacy data from a 12-month Phase II clinical trial...

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, today announced its financial and operational results for the year 2007. The...

      Invitation to Santhera's Annual Results Presentations   You are cordially invited to attend Santhera's 2007 Results Presentation which will be given by Klaus...

Dear Madam/Sir   Please note Santhera's financial reporting dates in 2008 as follows:   February 29, 2008: Publication of Full Year Results 2007; media conference and analyst...

Santhera Pharmaceuticals (SWX:SANN) was informed by Cominvest Asset Management GmbH, Ulrich Talmann, Platz der Einheit 1, DE-60327 Frankfurt am Main, Germany, that the public and non-public funds...

Santhera Pharmaceuticals (SWX:SANN) was informed by          GIMV NV, Karel Oomstraat 37, BE-2018 Antwerpen, Belgium, that the following funds under its...

Santhera Pharmaceuticals (SWX:SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, announces today that Health Canada has validated the Company's filing of a New Drug...

Santhera Pharmaceuticals (SWX:SANN), ein auf neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, gibt heute bekannt, dass die kanadische Arzneimittelbehörde Health...

Santhera Pharmaceuticals (SWX: SANN), a Swiss specialty pharmaceutical company focused on neuromuscular diseases, today holds its first R&D Day. The Company will present its successful...

Santhera Pharmaceuticals (SWX:SANN), ein auf neuromuskuläre Erkrankungen fokussiertes Schweizer Spezialitätenpharmaunternehmen, veranstaltet heute seinen ersten R&D Day. Dabei wird die...